Navigation Links
ThromboGenics Announces 2007 Full Year Results
Date:3/13/2008

LEUVEN, Belgium, March 13 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, today announces a business update and its financial results for the twelve month period ending 31 December 2007. During this period, ThromboGenics has raised additional funds to invest in its development pipeline and has continued to make good progress with its clinical programs.

Highlights

- Successful placing of a total of 5,166,517 shares in May 2007, which increased the Company's free float to 70%, and led to an improvement in stock liquidity. As part of this placement, ThromboGenics issued 2,214,030 new shares raising a total of EUR23.9m. These new funds have strengthened ThromboGenics financial position, and have allowed it to continue to advance its product pipeline and strengthen its operations. The Company's cash position amounted to EUR46.1m as of 31 December 2007.

- Achievement of key milestones with microplasmin for ophthalmic indications. Initiation of a Phase IIb clinical trial of microplasmin in vitrectomy (MIVI III - Microplasmin for Vitreous Injection) in the United States, as well as the initiation of two Phase IIa clinical trials of microplasmin in Europe, for vitreomacular traction and diabetic macular edema (MIVI IIT and MIVI II, respectively). Positive results from the Phase I MIVI I and the MIVI IIT were presented at two international ophthalmology conferences.

- Positive Phase I results with TB-402 (anti-factor VIII), in collaboration with BioInvent International. TB-402 is being developed as a long acting anti-coagulant for the treatment and prevention of deep vein thrombosis (DVT) and atrial fibrillation. The product will enter Phase II clinical studies by the end of 2008.

- Exciting pre-clinical results with TB-403 (anti-PIGF) were published in Cell as the featured article in the November 2, 2007 issue. The paper highlighted that antibodies against PIG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
2. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
3. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
8. EntreMed Announces 2008 Corporate and Clinical Program Priorities
9. Arpida Announces Full Year 2007 Financial Results
10. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
11. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 Sterlitech is proud ... membranes to its stable of products . ... weight cut-offs and include membrane filters with surface charges. ... in customer demand for our membrane process testing equipment, ... of flat sheet membranes,” explains Sterlitech President Mark Spatz. ...
(Date:8/28/2014)... this month, a report was created by Colorado ... Force on the performance of vehicles using an eco-friendly, ... fuel made from mustard seeds, offered great potential as ... friendly future. In fact, every branch of the U.S. ... foreign oil over the next few years. They will ...
(Date:8/27/2014)... TX (PRWEB) August 27, 2014 Green ... million in Series B funding and secured Otter Capital ... investment capital will accelerate commercialization of GGI’s Agriplier™ technology, ... crop types. , “Since our first meeting, we ... to the biological product space,” said Alan Sobba, President ...
(Date:8/27/2014)... is how plants survive impact by the huge ... while using this energy for photosynthesis. The hypothesis ... blades quickly dissipate the energy throughout the entire ... DTU Physics have now managed to successfully ,film, ... contain light-absorbing proteins which play a role in ...
Breaking Biology Technology:Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3DTU researchers film protein quake for the first time 2
... Operations, NAPLES, Fla., Sept. 8 Algenol ... third generation biofuels,technology, today announced the appointment of ... Coleman, currently the Vice-Principal Research and,Graduate Studies at ... of,experience in the fields of molecular biology and ...
... today announced,that the company has been selected to ... (http://www.advamed2008.com ), on Monday, September,22, 2008 in ... in the "Next Generation" category,Mr. Rudy Mazzocchi, the ... the increasing use of Vision Restoration Therapy,(VRT) among ...
... Corporation,s (Amex: ETC ) ("ETC" or the ... of two new contracts. The,contracts include a new ... Pharmaceutical Sterilization System to a new customer., ... 00 926 2151), also,known as "Big Bertha", is ...
Cached Biology Technology:Algenol Biofuels Appoints Chief Science Officer 2NovaVision CEO Named Presenter at the AdvaMed 2008 Conference 2Environmental Tectonics Corporation's Sterilization Systems Group Announces New Contracts 2Environmental Tectonics Corporation's Sterilization Systems Group Announces New Contracts 3
(Date:8/28/2014)... Ludwig-Maximilians-Universitaet (LMU) in Munich have assigned a number ... predatory arthropods. These animals lived in shallow marine ... forms found in Jurassic strata. , Before ... marine habitat and were fossilized some 435 million ... of the Silurian seas although they were ...
(Date:8/27/2014)... -- WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that it ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... consists of 2,000 shares of common stock and 2,000 ...
(Date:8/27/2014)... 2014. Using functional near infrared spectroscopy (fNIRS), Kessler ... between people with multiple sclerosis (MS) and healthy ... which brain activation was studied using fNIRS while ... and cognition using functional near infrared spectroscopy (fNIRS) ... 11 by Brain Imaging and Behavior . ...
Breaking Biology News(10 mins):Paleontology: Oldest representative of a weird arthropod group 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Kessler Foundation researchers publish first study of brain activation in MS using fNIRS 2
... simple kitchen sink experiment helped Northwestern University researchers discover ... to steep a good cup of tea, but they ... so can red wine, dark chocolate and cacao beans, ... work in a new way. (Polyphenols are naturally occurring ...
... Clean drinking water is a diminishing natural resource in ... Research Centre of Finland has developed a simple and ... Sources of phenolic compounds found in drinking water include ... are toxic and some may even cause cancer. , ...
... and poor soil have similar antioxidant activity to conventionally ... 21 in the open access journal PLOS ONE ... Brazil and colleagues from other institutions. Twelve fruit ... soils, were compared to conventional Red Delicious apples purchased ...
Cached Biology News:Sticking power of plant polyphenols used in new coatings 2Sticking power of plant polyphenols used in new coatings 3Finnish researchers develop quick test kit for detecting phenolic compounds in drinking water 2